B7H3 in vivo CAR-T (Azalea Therapeutics)

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameB7H3 in vivo CAR-T (Azalea Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy
Mechanisms of ActionAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAzalea Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesAzalea Therapeutics
Inactive CompaniesN/A
Active IndicationsSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A